Atypical pulmonary carcinoid tumour in a 28-year-old nonsmoker with Prader-Willi syndrome.

REFERENCES 1 Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005; 16: 1425–1433. 2 Tang X, Shigematsu H, Bekele BN, et al. EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. Cancer Res 2005; 65: 7568–7572. 3 Bolognia JL, Jorizzo JL, Rapini RP, eds. Dermatology. St Louis, Mosby, 2007. 4 Weiss SW, Goldblum JR, Enzinger FM, eds. Enzinger and Weiss’s Soft Tissue Tumours. 5 Edn. St Louis, Mosby, 2008. 5 Lee MW, Seo CW, Kim SW, et al. Cutaneous side effects in nonsmall cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor. Acta Derm Venereol 2004; 84: 23–26. 6 Boucher KW, Davidson K, Mirkhur B, et al. Paronychia induced by cetuximab, an antiepidermal growth factor receptor antibody. J Am Acad Dermatol 2002; 45: 632–633. 7 Dainichi T, Tanaka M, Tsuruta N, et al. Development of multiple paronychia and periungual granulation in patients treated with gefitinib, an inhibitor of epidermal growth factor receptor. Dermatology 2003; 207: 324–325. 8 Nakano J, Nakamura M. Paronychia induced by gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor. J Dermatol 2003; 30: 261–262. 9 Chang GC, Yang T-Y, Chen K-C, et al. Paronychia and skin hyperpigmentation induced by gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 2004; 22: 4646–4648.